Study design, materials and methods
It is an observational study on 60 patients diagnosed as OABS on history taking, examination and baseline investigations underwent urodynamic study (UDS), OABS Score and Incontinence Impact Questionnaire (IIQ). Subjects were randomised to 2 groups , Group 1 (solifenacin 5 mg) while Group II (tolterodine 4 mg) daily for 6 months and were followed up at 1, 3, and 6 months for OABS score, IIQ and any adverse events. UDS was repeated after 6 months.
Interpretation of results
Mean baseline value of OABS score was 8.5±1.87 (group I) and 8.57±1.5 (group II) which reduced to 5.6 (group I) and 5.57 (group II) in 3 months further reducing to 3.13 and 3.8 in 6 months. Baseline Mean IIQ was 12.77±3.88 (group I) and 11.77±2.9 (group II) reducing to 8.17(group I) and 4.67 (group II).
On UDS, baseline detrusor overactivity was 70% (group I)and 73.3% (group II) which reduced to 3.33% (group I) and 6.66% (group II) after 6 months. Baseline Mean Qmax (maximum flow rate) was 31.88±6.68 (group I) and 32.28±5.80 (group II) reducing to 19.60±3.53 (group I) and 18.62±3.21 (group II). Mean T Void (total time to void) at baseline was 33.89±6.87 (group I) and 32.03±5.08 (group II)which increased to 42.91±6.47 (group I) and 36.84±3.78 (group II). Adverse effects was higher in group II as compared to group I (p=0.02).